Does CABOZANTINIB S-MALATE Cause Malignant neoplasm progression? 2,718 Reports in FDA Database

Q: Does CABOZANTINIB S-MALATE cause Malignant neoplasm progression?

2,718 reports of Malignant neoplasm progression have been filed with the FDA for CABOZANTINIB S-MALATE, representing 6.9% of all CABOZANTINIB S-MALATE adverse event reports.

Q: How dangerous is Malignant neoplasm progression from CABOZANTINIB S-MALATE?

Of 2,718 reports, 909 (33.4%) resulted in death and 626 required hospitalization.

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 2,718 reports of Malignant neoplasm progression have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 6.9% of all adverse event reports for CABOZANTINIB S-MALATE.

2,718

Reports of Malignant neoplasm progression with CABOZANTINIB S-MALATE

6.9%

of all CABOZANTINIB S-MALATE reports

909

Deaths

626

Hospitalizations

How Dangerous Is Malignant neoplasm progression From CABOZANTINIB S-MALATE?

Of the 2,718 reports, 909 (33.4%) resulted in death, 626 (23.0%) required hospitalization, and 61 (2.2%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 2,718 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560) Death (2,504)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Malignant neoplasm progression Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

CABOZANTINIB S-MALATE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CABOZANTINIB S-MALATE Demographics